Search

Your search keyword '"Cosgaya, M."' showing total 8 results
Start Over Author "Cosgaya, M." Database OpenAIRE
8 results on '"Cosgaya, M."'

1. Staging Parkinson's Disease Combining Motor and Nonmotor Symptoms Correlates with Disability and Quality of Life

Author

Santos García, Diego, Deus Fonticoba, María Teresa de, Paz González, J. M., Cores Bartolomé, C., Valdés Aymerich, L., Muñoz Enríquez, J. G., Suárez, E., Jesús, S., Aguilar Barberà, Miquel, Pastor, P., Planellas, L. L., Cosgaya, M., García Caldentey, J., Caballol, N., Legarda, I., Hernández-Vara, Jorge, Cabo, I., López Manzanares, L., González Aramburu, I., Ávila-Rivera, M. A, Catalán, M. J., Nogueira, V., Puente, V., García Moreno, José Manuel, Borrué, C., Solano Vila, B., Álvarez Sauco, M., Vela, Lydia, Escalante, S., Cubo, Esther, Carrillo Padilla, F., Martínez Castrillo, J. C., Sánchez Alonso, P., Alonso Losada, M. G., López Ariztegui, N., Gastón, I., Kulisevsky, Jaime, Blázquez Estrada, M., Seijo, M., Rúiz Martínez, J., Valero, C., Kurtis, M., Fàbregues-Boixar i Nebot, Oriol de, González Ardura, J., Ordás, C., López Díaz, L., Mir, P., Martinez-Martin, Pablo, COPPADIS Study Group, None, Universitat Autònoma de Barcelona, Institut Català de la Salut, [Santos García D, Paz González JM, Cores Bartolomé C, Valdés Aymerich L, Muñoz Enríquez JG] CHUAC, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain. [De Deus Fonticoba T] CHUF, Complejo Hospitalario Universitario de Ferrol, A Coruña, Spain. [Hernández Vara J, de Fábregues O] Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus, Universidad de Sevilla. Departamento de Medicina, [Santos Garcia, D.] Complejo Hosp Univ A Coruna, CHUAC, La Coruna, Spain, [Paz Gonzalez, J. M.] Complejo Hosp Univ A Coruna, CHUAC, La Coruna, Spain, [Cores Bartolome, C.] Complejo Hosp Univ A Coruna, CHUAC, La Coruna, Spain, [Valdes Aymerich, L.] Complejo Hosp Univ A Coruna, CHUAC, La Coruna, Spain, [Munoz Enriquez, J. G.] Complejo Hosp Univ A Coruna, CHUAC, La Coruna, Spain, [De Deus Fonticoba, T.] Complejo Hosp Univ Ferrol, CHUF, La Coruna, Spain, [Suarez, E.] Complejo Hosp Univ Ferrol, CHUF, La Coruna, Spain, [Jesus, S.] Univ Seville, Serv Neurol & Neurofisiol Clin, Unidad Trastornos Movimiento, Hosp Univ Virgen Rocio,CSIC,Inst Biomed Sevilla, Seville, Spain, [Mir, P.] Univ Seville, Serv Neurol & Neurofisiol Clin, Unidad Trastornos Movimiento, Hosp Univ Virgen Rocio,CSIC,Inst Biomed Sevilla, Seville, Spain, [Jesus, S.] Ctr Invest Biomed Red Enfermedades Neurodegnerat, CIBERNED, Madrid, Spain, [Gonzalez Aramburu, I.] Ctr Invest Biomed Red Enfermedades Neurodegnerat, CIBERNED, Madrid, Spain, [Kulisevsky, J.] Ctr Invest Biomed Red Enfermedades Neurodegnerat, CIBERNED, Madrid, Spain, [Mir, P.] Ctr Invest Biomed Red Enfermedades Neurodegnerat, CIBERNED, Madrid, Spain, [Martinez-Martin, P.] Ctr Invest Biomed Red Enfermedades Neurodegnerat, CIBERNED, Madrid, Spain, [Aguilar, M.] Hosp Univ Mutua Terrassa, Terrassa, Spain, [Pastor, P.] Hosp Univ Mutua Terrassa, Terrassa, Spain, [Planellas, L. L.] Hosp Clin Barcelona, Barcelona, Spain, [Cosgaya, M.] Hosp Clin Barcelona, Barcelona, Spain, [Garcia Caldentey, J.] Ctr Neurol Oms 42, Palma de Mallorca, Spain, [Caballol, N.] Hosp Moises Broggi, Consorci Sanitari Integral, Barcelona, Spain, [Legarda, I.] Hosp Univ Son Espases, Palma de Mallorca, Spain, [Hernandez Vara, J.] Hosp Univ Vall Hebron, Barcelona, Spain, [de Fabregues, O.] Hosp Univ Vall Hebron, Barcelona, Spain, [Cabo, I.] Complejo Hosp Univ Pontevedra CHOP, Pontevedra, Spain, [Seijo, M.] Complejo Hosp Univ Pontevedra CHOP, Pontevedra, Spain, [Lopez Manzanares, L.] Hosp Univ La Princesa, Madrid, Spain, [Gonzalez Aramburu, I.] Hosp Univ Marques Valdecilla, Santander, Spain, [Avila Rivera, M. A.] Hosp Gen Hosp, Consorci Sanitari Integral, Barcelona, Spain, [Catalan, M. J.] Hosp Univ Clin San Carlos, Madrid, Spain, [Nogueira, V.] Hosp Da Costa, Lugo, Spain, [Puente, V.] Hosp del Mar, Barcelona, Spain, [Garcia Moreno, J. M.] Hosp Univ Virgen Macarena, Seville, Spain, [Borrue, C.] Hosp Infanta Sofia, Madrid, Spain, [Solano Vila, B.] Inst Catala Salut, Inst Assistencia Sanitaria IAS, Girona, Spain, [Alvarez Sauco, M.] Hosp Gen Univ Elche, Elche, Spain, [Vela, L.] Fdn Hosp Alcorcon, Madrid, Spain, [Escalante, S.] Hosp Tortosa Verge Cinta IITVC, Tarragona, Spain, [Cubo, E.] Complejo Asistencial Univ Burgos, Burgos, Spain, [Carrillo Padilla, F.] Hosp Univ Canarias, San Cristobal De Laguna, Santa Cruz De T, Spain, [Martinez Castrillo, J. C.] Hosp Univ Ramon y Cajal, Madrid, Spain, [Sanchez Alonso, P.] Hosp Univ Puerta Hierro, Madrid, Spain, [Alonso Losada, M. G.] Complejo Hosp Univ Vigo CHUVI, Hosp Alvaro Cunqueiro, Vigo, Spain, [Lopez Ariztegui, N.] Complejo Hosp Toledo, Toledo, Spain, [Gaston, I.] Complejo Hosp Navarra, Pamplona, Spain, [Kulisevsky, J.] Hosp Santa Creu & Sant Pau, Barcelona, Spain, [Blazquez Estrada, M.] Hosp Univ Cent Asturias, Oviedo, Spain, [Ruiz Martinez, J.] Hosp Univ Donostia, San Sebastian, Spain, [Valero, C.] Hosp Arnau Vilanova, Valencia, Spain, [Kurtis, M.] Hosp Ruber Int, Madrid, Spain, [Gonzalez Ardura, J.] Hosp Univ Lucus Augusti HULA, Lugo, Spain, [Ordas, C.] Hosp Rey Juan Carlos, Madrid, Spain, [Lopez Diaz, L.] Complejo Hosp Univ Orense CHUO, Orense, Spain, and [COPPADIS Study Grp] Fdn Curemos Parkinson, C Juana Vega 23 2, La Coruna 15004, Spain

Subjects
medicine.medical_specialty, Discapacitats, Parkinson's disease, Article Subject, Degenerative Disorder, Parkinson, Malaltia de - Prognosi, Neuroscience (miscellaneous), Disease, Stage ii, personas::personas con discapacidad [DENOMINACIONES DE GRUPOS], Parkinson’s Disease, 03 medical and health sciences, 0302 clinical medicine, Quality of life, enfermedades del sistema nervioso::enfermedades del sistema nervioso central::enfermedades cerebrales::enfermedades de los ganglios basales::trastornos parkinsonianos::enfermedad de Parkinson [ENFERMEDADES], Malaltia de Parkinson, Internal medicine, medicine, Motor and nonmotor symptoms (NMS), Stage (cooking), RC346-429, 030304 developmental biology, ambiente y salud pública::salud pública::medidas epidemiológicas::demografía::estado de salud::calidad de vida [ATENCIÓN DE SALUD], Subtypes, 0303 health sciences, Questionnaire, business.industry, Neurodegenerative disorder, medicine.disease, humanities, Scale, Psychiatry and Mental health, Environment and Public Health::Public Health::Epidemiologic Measurements::Demography::Health Status::Quality of Life [HEALTH CARE], Impact, Persons::Disabled Persons [NAMED GROUPS], Nervous System Diseases::Central Nervous System Diseases::Brain Diseases::Basal Ganglia Diseases::Parkinsonian Disorders::Parkinson Disease [DISEASES], Neurology. Diseases of the nervous system, Neurology (clinical), Stage iv, business, 030217 neurology & neurosurgery, Qualitat de vida - Avaluació, Research Article
Abstract

COPPADIS Study Group., [Introduction] In a degenerative disorder such as Parkinson’s disease (PD), it is important to establish clinical stages that allow to know the course of the disease. Our aim was to analyze whether a scale combining Hoehn and Yahr’s motor stage (H&Y) and the nonmotor symptoms burden (NMSB) (assessed by the nonmotor symptoms scale (NMSS)) provides information about the disability and the patient’s quality of life (QoL) with regard to a defined clinical stage., [Materials and Methods] Cross-sectional study in which 603 PD patients from the COPPADIS cohort were classified according to H&Y (1, stage I; 2, stage II; 3, stage III; 4, stage IV/V) and NMSB (A: NMSS = 0–20; B: NMSS = 21–40; C: NMSS = 41–70; D: NMSS ≥ 71) in 16 stages (HY.NMSB, from 1A to 4D). QoL was assessed with the PDQ-39SI, PQ-10, and EUROHIS-QOL8 and disability with the Schwab&England ADL (Activities of Daily Living) scale., [Results] A worse QoL and greater disability were observed at a higher stage of H&Y and NMSB (). Combining both (HY.NMSB), patients in stages 1C and 1D and 2C and 2D had significantly worse QoL and/or less autonomy for ADL than those in stages 2A and 2B and 3A and 3B, respectively (; e.g., PDQ-39SI in 1D [n = 15] vs 2A [n = 101]: 28.6 ± 17.1 vs 7.9 ± 5.8; )., [Conclusion] The HY.NMSB scale is simple and reflects the degree of patient involvement more accurately than the H&Y. Patients with a lower H&Y stage may be more affected if they have a greater NMS burden.

Published
2021

2. Constipation Predicts Cognitive Decline in Parkinson's Disease: Results from the COPPADIS Cohort at 2-Year Follow-up and Comparison with a Control Group

Author

Santos García D, García Roca L, de Deus Fonticoba T, Cores Bartolomé C, Naya Ríos L, Canfield H, Paz González JM, Martínez Miró C, Jesús S, Aguilar M, Pastor P, Planellas L, Cosgaya M, García Caldentey J, Caballol N, Legarda I, Hernández Vara J, Cabo I, López Manzanares L, González Aramburu I, Ávila Rivera MA, Gómez Mayordomo V, Nogueira V, Puente V, Dotor García-Soto J, Borrué C, Solano Vila B, Álvarez Sauco M, Vela L, Escalante S, Cubo E, Carrillo Padilla F, Martínez Castrillo JC, Sánchez Alonso P, Alonso Losada MG, López Ariztegui N, Gastón I, Kulisevsky J, Blázquez Estrada M, Seijo M, Rúiz Martínez J, Valero C, Kurtis M, de Fábregues O, González Ardura J, Alonso Redondo R, Ordás C, López Díaz L LM, McAfee D, Martinez-Martin P, Mir P, and COPPADIS Study Group

Subjects
impairment, Cognition, Parkinson's disease, constipation, non-motor symptoms
Abstract

Background: Constipation has been linked to cognitive impairment development in Parkinson's disease (PD). Objective: Our aim was to analyze cognitive changes observed in PD patients and controls from a Spanish cohort with regards to the presence or not of constipation. Methods: PD patients and controls recruited from 35 centers of Spain from the COPPADIS cohort from January 2016 to November 2017 were followed-up during 2 years. The change in cognitive status from baseline (V0) to 2-year follow-up was assessed with the PD-CRS (Parkinson's Disease Cognitive Rating Scale). Subjects with a score >= 1 on item 21 of the NMSS (Non-Motor Symptoms Scale) at baseline (V0) were considered as "with constipation". Regression analyses were applied for determining the contribution of constipation in cognitive changes. Results: At V0, 39.7% (198/499) of PD patients presented constipation compared to 11.4% of controls (14/123) (p < 0.0001). No change was observed in cognitive status (PD-CRS total score) neither in controls without constipation (from 100.24 +/- 13.72 to 100.27 +/- 13.68; p = 0.971) and with constipation (from 94.71 +/- 10.96 to 93.93 +/- 13.03; p = 0.615). The PD-CRS total score decreased significantly in PD patients with constipation (from 89.14 +/- 15.36 to 85.97 +/- 18.09; p

Published
2022

4. Diplopia Is Frequent and Associated with Motor and Non-Motor Severity in Parkinson’s Disease: Results from the COPPADIS Cohort at 2-Year Follow-Up

Author

Garcia D, Rios L, Fonticoba T, Bartolome C, Roca L, Painceiras M, Miro C, Canfield H, Jesus S, Aguilar M, Pastor P, Cosgaya M, Caldentey J, Caballol N, Legarda I, Vara J, Cabo I, Manzanares L, Aramburu I, Rivera M, Mayordomo V, Nogueira V, Puente V, Dotor J, Borrue C, Vila B, Sauco M, Vela L, Escalante S, Cubo E, Padilla F, Castrillo J, Alonso P, Losada M, Ariztegui N, Gaston I, Kulisevsky J, Estrada M, Seijo M, Martinez J, Valero C, Kurtis M, de Fabregues O, Ardura J, Redondo R, Ordas C, Diaz L, McAfee D, Martinez-Martin P, Mir P, COPPADIS Study Grp, Instituto de Salud Carlos III, Takeda Pharmaceutical Company, International Parkinson and Movement Disorder Society, AbbVie Pharmaceuticals, Abbott Laboratories, Allergan Foundation, BIAL Foundation, Merz Pharma, UCB Pharma, Zambon, Ministerio de Economía y Competitividad (España), European Commission, Junta de Andalucía, Sociedad Andaluza de Neurología, Jacques and Gloria Gossweiler Foundation, Fundación Alicia Koplowitz, Fundación Mutua Madrileña, Institut Català de la Salut, [Santos-García D, Naya Rios L, Cores Bartolomé C, García Roca L, Feal Painceiras M, Martínez Miró C] Complejo Hospitalario Universitario de A Coruña (CHUAC), A Coruña, Spain. [de Deus Fonticoba T, Canfield H] Complejo Hospitalario Universitario de Ferrol (CHUF), A Coruña, Spain. [Jesús S, Mir P] Unidad de Trastornos del Movimiento, Servicio de Neurología y Neurofisiología Clínica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío, Universidad de Sevilla, Sevilla, Spain. Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain. [Aguilar M, Pastor P] Hospital Universitari Mutua de Terrassa, Terrassa , Spain. [Cosgaya M] Hospital Clínic de Barcelona, Barcelona, Spain. [García-Caldentey J] Centro Neurológico Oms, Palma de Mallorca, Spain. [Caballol N] Consorci Sanitari Integral, Hospital Moisés Broggi, Barcelona, Spain. [Legarda I] Hospital Universitari Son Espases, Palma de Mallorca, Spain. [Hernández-Vara J, de Fábregues O] Vall d'Hebron Hospital Universitari, Barcelona, Spain. [Cabo López I, Seijo M] Complexo Hospitalario Universitario de Pontevedra (CHOP), Pontevedra, Spain. [López Manzanares L] Hospital Universitario La Princesa, Madrid, Spain. [González Aramburu I] Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain. Hospital Universitario Marqués de Valdecilla, Santander, Spain. [Ávila Rivera MA] Consorci Sanitari Integral, Hospital General de L'Hospitalet, L'Hospitalet de Llobregat, Spain. [Gómez-Mayordomo V] Hospital Universitario Clínico San Carlos, Madrid, Spain. [Nogueira V] Hospital Da Costa, Burela, Lugo, Spain. [Puente V] Hospital del Mar, Barcelona, Spain. [Dotor J] Hospital Universitario Virgen Macarena, Sevilla, Spain. [Borrué C] Hospital Infanta Sofía, Madrid, Spain. [Solano Vila B] Institut d'Assistència Sanitària (IAS), Institut Català de la Salut (ICS), Salt, Spain. [Álvarez Sauco M] Hospital General Universitario de Elche, Elche, Spain. [Vela-Desojo L] Fundación Hospital de Alcorcón, Madrid, Spain. [Escalante S] Hospital de Tortosa Verge de la Cinta (HTVC), Tortosa, Spain. [Cubo E] Complejo Asistencial Universitario de Burgos, Burgos, Spain. [Carrillo-Padilla F] Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain. [Martínez Castrillo JC] Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain. [Sánchez Alonso P] Hospital Universitario Puerta de Hierro, Madrid, Spain. [Alonso Losada MG] Hospital Álvaro Cunqueiro, Complexo Hospitalario Universitario de Vigo (CHUVI), Vigo, Spain. [López-Ariztegui N] Complejo Hospitalario de Toledo, Toledo, Spain. [Gastón I] Complejo Hospitalario de Navarra, Pamplona, Spain. [Kulisevsky J] Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain. Hospital de Sant Pau, Barcelona, Spain. [Blázquez Estrada M] Hospital Universitario Central de Asturias, Oviedo, Spain. [Ruiz-Martínez J] Hospital Universitario Donostia, San Sebastián, Spain. [Valero C] Hospital Arnau de Vilanova, València, Spain. [Kurtis M] Hospital Ruber Internacional, Madrid, Spain. [González Ardura J] Hospital de Cabueñes, Gijón, Spain. [Alonso Redondo R] Universitario Lucus Augusti (HULA), Lugo, Spain. [Ordás C] Hospital Rey Juan Carlos, Madrid, Spain. [López Díaz LM] Complexo Hospitalario Universitario de Ourense (CHUO), Ourense, Spain. [McAfee D] University of Maryland School of Medicine, Baltimore, USA. [Martinez-Martin P] Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain, and Institut d'Assistència Sanitària

Subjects
enfermedades del sistema nervioso::enfermedades del sistema nervioso central::enfermedades del sistema nervioso::enfermedades del sistema nervioso central::trastornos del movimiento::trastornos parkinsonianos::enfermedades del sistema nervioso::enfermedad de Parkinson [ENFERMEDADES], Medicine (General), changes, motor, Parkinson’s disease, phenotype, PIGD, Tremor, endocrine system diseases, genetic structures, Parkinson's disease, Clinical Biochemistry, Tremolor, Nervous System Diseases::Central Nervous System Diseases::Nervous System Diseases::Central Nervous System Diseases::Movement Disorders::Parkinsonian Disorders::Nervous System Diseases::Parkinson Disease [DISEASES], enfermedades del sistema nervioso::manifestaciones neurológicas::discinesias::temblor [ENFERMEDADES], Article, eye diseases, Fenotip, R5-920, Genetic Phenomena::Phenotype [PHENOMENA AND PROCESSES], Parkinson, Malaltia de, fenómenos genéticos::fenotipo [FENÓMENOS Y PROCESOS], Pathological Conditions, Signs and Symptoms::Signs and Symptoms::Neurologic Manifestations::Dyskinesias::Tremor [DISEASES]
Abstract

[Background and objective] Diplopia is relatively common in Parkinson’s disease (PD) but is still understudied. Our aim was to analyze the frequency of diplopia in PD patients from a multicenter Spanish cohort, to compare the frequency with a control group, and to identify factors associated with it., [Patients and Methods] PD patients who were recruited from January 2016 to November 2017 (baseline visit; V0) and evaluated again at a 2-year ± 30 days follow-up (V2) from 35 centers of Spain from the COPPADIS cohort were included in this longitudinal prospective study. The patients and controls were classified as “with diplopia” or “without diplopia” according to item 15 of the Non-Motor Symptoms Scale (NMSS) at V0, V1 (1-year ± 15 days), and V2 for the patients and at V0 and V2 for the controls., [Results] The frequency of diplopia in the PD patients was 13.6% (94/691) at V0 (1.9% in controls [4/206]; p < 0.0001), 14.2% (86/604) at V1, and 17.1% (86/502) at V2 (0.8% in controls [1/124]; p < 0.0001), with a period prevalence of 24.9% (120/481). Visual hallucinations at any visit from V0 to V2 (OR = 2.264; 95%CI, 1.269–4.039; p = 0.006), a higher score on the NMSS at V0 (OR = 1.009; 95%CI, 1.012–1.024; p = 0.015), and a greater increase from V0 to V2 on the Unified Parkinson’s Disease Rating Scale–III (OR = 1.039; 95%CI, 1.023–1.083; p < 0.0001) and Neuropsychiatric Inventory (OR = 1.028; 95%CI, 1.001–1.057; p = 0.049) scores were independent factors associated with diplopia (R2 = 0.25; Hosmer and Lemeshow test, p = 0.716)., [Conclusions] Diplopia represents a frequent symptom in PD patients and is associated with motor and non-motor severity., Martínez-Martin P. has received honoraria from National School of Public Health (ISCIII), Editori-al Viguera and Takeda Pharmaceuticals for lecturing in courses, and from the International Parkinson and Movement Disorder Society (MDS) for management of the Program on Rating Scales. Mir P. has received honoraria from AbbVie, Abbott, Allergan, Bial, Merz, UCB, and Zambon and have received grants from the Spanish Ministry of Economy and Competitiveness [PI16/01575], co-founded by ISCIII (Subdirección General de Evaluación y Fomento de la Investigación) and by Fondo Europeo de Desarrollo Regional (FEDER), the Consejería de Economía, Innovación, Ciencia y Empleo de la Junta de Andalucía [CVI-02526, CTS-7685], the Consejería de Salud y Bienestar Social de la Junta de Andalucía [ PI-0437-2012, PI-0471-2013], the Sociedad Andaluza de Neurología, the Jacques and Gloria Gossweiler Foundation, the Fundación Alicia Koplowitz, the Fundación Mutua Madrileña.

Published
2021

5. Predictors of clinically significant quality of life impairment in Parkinson's disease

Author

Garcia D, Fonticoba T, Cores C, Munoz G, Gonzalez J, Miro C, Suarez E, Jesus S, Aguilar M, Pastor P, Planellas L, Cosgaya M, Caldentey J, Caballol N, Legarda I, Vara J, Cabo I, Manzanares L, Aramburu I, Rivera M, Catalan M, Nogueira V, Puente V, de Arcos M, Borrue C, Vila B, Sauco M, Vela L, Escalante S, Cubo E, Padilla F, Castrillo J, Alonso P, Losada M, Ariztegui N, Gaston I, Clavero P, Kulisevsky J, Estrada M, Seijo M, Martinez J, Valero C, Kurtis M, de Fabregues O, Ardura J, Ordas C, Diaz L, McAfee D, Martinez-Martin P, Mir P, and COPPADIS Study Grp

Abstract

Quality of life (QOL) plays an important role in independent living in Parkinson's disease (PD) patients, being crucial to know what factors impact QoL throughout the course of the disease. Here we identified predictors of QoL impairment in PD patients from a Spanish cohort. PD patients recruited from 35 centers of Spain from the COPPADIS cohort from January 2016, to November 2017, were followed up during 2 years. Health-related QoL (HRQoL) and global QoL (GQoL) were assessed with the 39-item Parkinson's disease Questionnaire (PDQ-39) and the EUROHIS-QOL 8-item index (EUROHIS-QOL8), respectively, at baseline (V0) and at 24 months +/- 1 month (V2). Clinically significant QoL impairment was defined as presenting an increase (PDQ-39SI) or decrement (EUROHIS-QOL8) at V2 >= 10% of the score at baseline (V0). A comparison with a control group was conducted for GQoL. GQoL did not change significantly in PD patients (N = 507; p = 0.686) or in the control group (N = 119; p = 0.192). The mean PDQ-39SI was significantly increased in PD patients (62.7 +/- 8.5 years old; 58.8% males; N = 500) by 21.6% (from 16.7 +/- 13 to 20.3 +/- 16.4; p < 0.0001) at V2. Ninety-three patients (18.6%) presented a clinically significant HRQoL impairment at V2. To be younger (OR = 0.896; 95% CI 0.829-0.968; p = 0.006), to be a female (OR = 4.181; 95% CI 1.422-12.290; p = 0.009), and to have a greater increase in BDI-II (Beck Depression Inventory-II) (OR = 1.139; 95% CI 1.053-1.231; p = 0.001) and NMSS (Non-Motor Symptoms Scale) (OR = 1.052; 95% CI 1.027-1.113; p < 0.0001) total scores from V0 to V2 were associated with clinically significant HRQoL impairment at the 2-year follow-up (Hosmer-Lemeshow test, p = 0.665; R-2 = 0.655). An increase in >= 5 and >= 10 points of BDI-II and NMSS total score at V2 multiplied the probability of presenting clinically significant HRQoL impairment by 5 (OR = 5.453; 95% CI 1.663-17.876; p = 0.005) and 8 (OR = 8.217; 95% CI, 2.975-22.696; p = 0.002), respectively. In conclusion, age, gender, mood, and non-motor impairment were associated with clinically significant HRQoL impairment after the 2-year follow-up in PD patients.

Published
2021

6. Predictors of clinically significant quality of life impairment in Parkinson's disease

Author

Garcia, DS, Fonticoba, TD, Cores, C, Munoz, G, Gonzalez, JMP, Miro, CM, Suarez, E, Jesus, S, Aguilar, M, Pastor, P, Planellas, L, Cosgaya, M, Caldentey, JG, Caballol, N, Legarda, I, Vara, JH, Cabo, I, Manzanares, LL, Aramburu, IG, Rivera, MAA, Catalan, MJ, Nogueira, V, Puente, V, de Arcos, MR, Borrue, C, Vila, BS, Sauco, MA, Vela, L, Escalante, S, Cubo, E, Padilla, FC, Castrillo, JCM, Alonso, PS, Losada, MGA, Ariztegui, NL, Gaston, I, Clavero, P, Kulisevsky, J, Estrada, MB, Seijo, M, Martinez, JR, Valero, C, Kurtis, M, de Fabregues, O, Ardura, JG, Ordas, C, Diaz, LML, McAfee, D, Martinez-Martin, P, and Mir, P

Subjects
humanities
Abstract

Quality of life (QOL) plays an important role in independent living in Parkinson's disease (PD) patients, being crucial to know what factors impact QoL throughout the course of the disease. Here we identified predictors of QoL impairment in PD patients from a Spanish cohort. PD patients recruited from 35 centers of Spain from the COPPADIS cohort from January 2016, to November 2017, were followed up during 2 years. Health-related QoL (HRQoL) and global QoL (GQoL) were assessed with the 39-item Parkinson's disease Questionnaire (PDQ-39) and the EUROHIS-QOL 8-item index (EUROHIS-QOL8), respectively, at baseline (V0) and at 24 months +/- 1 month (V2). Clinically significant QoL impairment was defined as presenting an increase (PDQ-39SI) or decrement (EUROHIS-QOL8) at V2 >= 10% of the score at baseline (V0). A comparison with a control group was conducted for GQoL. GQoL did not change significantly in PD patients (N = 507; p = 0.686) or in the control group (N = 119; p = 0.192). The mean PDQ-39SI was significantly increased in PD patients (62.7 +/- 8.5 years old; 58.8% males; N = 500) by 21.6% (from 16.7 +/- 13 to 20.3 +/- 16.4; p < 0.0001) at V2. Ninety-three patients (18.6%) presented a clinically significant HRQoL impairment at V2. To be younger (OR = 0.896; 95% CI 0.829-0.968; p = 0.006), to be a female (OR = 4.181; 95% CI 1.422-12.290; p = 0.009), and to have a greater increase in BDI-II (Beck Depression Inventory-II) (OR = 1.139; 95% CI 1.053-1.231; p = 0.001) and NMSS (Non-Motor Symptoms Scale) (OR = 1.052; 95% CI 1.027-1.113; p < 0.0001) total scores from V0 to V2 were associated with clinically significant HRQoL impairment at the 2-year follow-up (Hosmer-Lemeshow test, p = 0.665; R-2 = 0.655). An increase in >= 5 and >= 10 points of BDI-II and NMSS total score at V2 multiplied the probability of presenting clinically significant HRQoL impairment by 5 (OR = 5.453; 95% CI 1.663-17.876; p = 0.005) and 8 (OR = 8.217; 95% CI, 2.975-22.696; p = 0.002), respectively. In conclusion, age, gender, mood, and non-motor impairment were associated with clinically significant HRQoL impairment after the 2-year follow-up in PD patients.

Published
2021

7. Mood in Parkinson's disease: From early- to late-stage disease

Author

Santos-Garcia D, De Deus F, Cores B, Valdes A, Suarez C, Aneiros A, Jesus S, Aguilar M, Pastor P, Planellas L, Cosgaya M, Garcia C, Caballol N, Legarda I, Hernandez V, Cabo I, Lopez M, Gonzalez A, Avila R, Jose C, Nogueira V, Puente V, Garcia M, Borrue C, Solano V, Alvarez S, Vela L, Escalante S, Cubo E, Carrillo P, Martinez C, Sanchez A, Alonso L, Lopez A, Gaston I, Kulisevsky J, Blazquez E, Seijo M, Ruiz M, Valero C, Kurtis M, de Fabregues-Boixar O, Prieto J, Lopez D, McAfee D, Mir P, and COPPADIS Study Grp

Subjects
s disease, quality of life, mood, depression, disease duration, Parkinson&apos, Parkinson's disease
Abstract

BACKGROUND: Although depression is known to be frequent in Parkinson's disease (PD), it is unclear how mood can change and/or impact on patient's quality of life (QoL) over time. Our aim was to analyze the frequency of depression, mood related factors and the contribution of mood to a patient's QoL perception in regard to disease duration. METHODS: PD patients recruited from the COPPADIS cohort from January 2016 to November 2017 were included in this cross-sectional study. Three groups were defined

Published
2021

8. Motor Fluctuations development is associated with non-motor symptoms burden progression in Parkinson's disease patients: A 2-year follow-up study

Author

Santos, D., Deus, T., Cores, C., Feal Painceiras, M., Suarez Castro, E., Martinez, C., Jesus, S., Aguilar, M., Pastor, P., Planellas, L., Cosgaya, M., Garcia Caldentey, J., Caballol, N., Legarda, I., Hernandez Vara, J., Cabo, I., Lopez Manzanares, L., Gonzalez Aramburu, I., Avila, M., Gomez Mayordomo, V., Nogueira, V., Puente, V., Dotor, J., Borrue, C., Solano, B., Alvarez Sauco, M., Vela, L., Escalante, S., Cubo, E., Carrillo, F., Martinez Castrillo, J., Sanchez Alonso, P., Alonso Losada, M., Lopez Ariztegui, N., Gaston, I., Jaime Kulisevsky, Blazquez, M., Seijo, M., Ruiz Martinez, J., Valero, C., Kurtis, M., Fabregues, O., Gonzalez, J., Alonso Redondo, R., Ordas, C., Lopez Diaz, L., Mcafee, D., Martinez Martin, P., Mir, P., and Coppadis, C.

Subjects
motor fluctuations, Parkinson's disease, follow-up, non-motor symptoms, burden
Abstract

Objective: The aim of the present study was to analyze the progression of non-motor symptoms (NMS) burden in Parkinson's disease (PD) patients regarding the development of motor fluctuations (MF). Methods: PD patients without MF at baseline, who were recruited from January 2016 to November 2017 (V0) and evaluated again at a 2-year follow-up (V2) from 35 centers of Spain from the COPPADIS cohort, were included in this analysis. MF development at V2 was defined as a score >= 1 in the item-39 of the UPDRS-Part IV, whereas NMS burden was defined according to the Non-motor Symptoms Scale (NMSS) total score. Results: Three hundred and thirty PD patients (62.67 +/- 8.7 years old; 58.8% males) were included. From V0 to V2, 27.6% of the patients developed MF. The mean NMSS total score at baseline was higher in those patients who developed MF after the 2-year follow-up (46.34 +/- 36.48 vs. 34.3 +/- 29.07; p = 0.001). A greater increase in the NMSS total score from V0 to V2 was observed in patients who developed MF (+16.07 +/- 37.37) compared to those who did not develop MF (+6.2 +/- 25.8) (p = 0.021). Development of MF after a 2-year follow-up was associated with an increase in the NMSS total score (beta = 0.128; p = 0.046) after adjustment to age, gender, years from symptoms onset, levodopa equivalent daily dose (LEDD) and the NMSS total score at baseline, and the change in LEDD from V0 to V2. Conclusions: In PD patients, the development of MF is associated with a greater increase in the NMS burden after a 2-year follow-up.

Catalog

Books, media, physical & digital resources
See catalog results